Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12

Charles S. Tannenbaum, Nicole B. Wicker, David A. Armstrong, +4

The Journal of Immunology

Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.

Robert G. Uzzo, Patricia Rayman, Vladimir Kolenko, +12

PubMed

ApoptosisImmunologyImmunoeditingCell DeathImmune Recognition +15

Sensitive in situ hybridization with catalyzed reporter deposition, streptavidin-Nanogold, and silver acetate autometallography: detection of single-copy human papillomavirus.

Ingeborg Zehbe, GW Hacker, Su H, +3

PubMed

Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas

Vladimir Kolenko, Qing Wang, M.C. Riedy, +9

The Journal of Immunology

T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present

Qing Wang, Jill Stanley, S. Kudoh, +6

The Journal of Immunology

G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer

Venugopalan Cheriyath, M A Kuhns, Barbara Jacobs, +5

Oncogene

Estrogen-induced Survival ProteinBreast OncologyPoor OutcomesMedicineBreast Cancer +6

Tumor‐Infiltrating Lymphocytes in Patients with Renal‐Cell Carcinoma

James H. Finke, R Tubbs, Barbara A. Connelly, +2

Annals of the New York Academy of Sciences

Lymphoid NeoplasiaUrologyCancer ImmunosurveillanceGenitourinary CancerRenal Pathology +4

Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.

G. Thomas Budd, B Osgood, Barbara P. Barna, +7

PubMed

ImmunotoxicologyImmunologyPathologyMalignant MelanomaImmune System +17

Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma.

Ronald M. Bukowski, Patricia Rayman, Luis Moltó, +10

PubMed

ImmunologyRenal InflammationPathologyImmunotherapyTumor Biology +16

Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.

Ronald M. Bukowski, Sudish C. Murthy, J. Sergi, +6

PubMed

Ril-2 4.5ImmunologyPharmacotherapyEndometrial CarcinomaImmunotherapy +14